Schonfeld Strategic Advisors LLC Inozyme Pharma, Inc. Transaction History

Schonfeld Strategic Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.14 - $7.66 $140,346 - $259,674	-33,900 Reduced 31.19%	74,800 $572,000
Q4 2023 Feb 14, 2024	SELL	$2.71 - $4.5 $550,617 - $914,310	-203,180 Reduced 65.15%	108,700 $463,000
Q3 2023 Nov 14, 2023	BUY	$4.09 - $7.0 $990,107 - $1.69 Million	242,080 Added 346.82%	311,880 $1.31 Million
Q2 2023 Aug 14, 2023	BUY	$4.93 - $6.74 $203,116 - $277,688	41,200 Added 144.06%	69,800 $388,000
Q1 2023 May 15, 2023	BUY	$1.3 - $5.73 $37,180 - $163,878	28,600 New	28,600 $163,000

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $161M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.